Controlled Release of Small Molecules for Cardiac Differentiation of Pluripotent Stem Cells
Publication: Tissue Engineering Part A
Volume 24, Issue Number 23-24
Abstract
Induced pluripotent stem cells (iPSCs) have been shown to differentiate to functional cardiomyocytes (CM) with high efficiency through temporally controlled inhibition of the GSK3/Wnt signaling pathways. In this study, we investigated the ability of temporally controlled release of GSK3/Wnt small-molecule inhibitors to drive cardiac differentiation of iPSC without manual intervention. Porous silica particles were loaded with GSK3 inhibitor CHIR99021 or Wnt inhibitor IWP2, and the particles containing IWP2 were coated with 5 wt% poly(lactic-co-glycolic acid) 50:50 to delay release by ∼72 h. iPSCs reprogrammed through mRNA transfection were cultured with these particles up to 30 days. High-performance liquid chromatography suggests a burst release of CHIR99021 within the first 24 h and a delayed release of IWP2 after 72 h. Annexin V/propidium iodide staining did not show a significant effect on apoptosis or necrosis rates. Cultured cells upregulated both early (Nkx 2.5, Isl-1) and late (cTnT, MHC, Cx43) cardiac markers, assayed with a quantitative real-time polymerase chain reaction, and began spontaneous contraction at 3.0 ± 0.6 Hz at 15–21 days after the start of differentiation. CM had clear sarcomeric striations when stained for β-myosin heavy chain, and showed expression and punctate membrane localization of gap junction protein Connexin43. Calcium and voltage-sensitive imaging showed both action potential and calcium transients typical of immature CM. This study showed that the cardiac differentiation of pluripotent stem cells can be directed by porous silica vectors with temporally controlled release of small-molecule inhibitors. These results suggest methods for automating and eliminating variability in manual maintenance of inhibitor concentrations in the differentiation of pluripotent stem cells to CM.
Get full access to this article
View all available purchase options and get full access to this article.
References
1. Vunjak-Novakovic G., Tandon N., Godier A., et al. Challenges in cardiac tissue engineering. Tissue Eng Part B Rev 16, 169, 2010.
2. Maltsev V.A., Rohwedel J., Hescheler J., and Wobus A.M. Embryonic stem cells differentiate in vitro into cardiomyocytes representing sinusnodal, atrial and ventricular cell types. Mech Dev 44, 41, 1993.
3. Julian D.G., Camm A.J., Frangin G., et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 349, 667, 1997.
4. Lian X., Hsiao C., Wilson G., et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A 109, E1848, 2012.
5. Lian X., Zhang J., Azarin S.M., et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat Protoc 8, 162, 2013.
6. Martinez J.O., Chiappini C., Ziemys A., et al. Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. Biomaterials 34, 8469, 2013.
7. Minardi S., Pandolfi L., Taraballi F., et al. PLGA-mesoporous silicon microspheres for the in vivo controlled temporospatial delivery of proteins. ACS Appl Mater Interfaces 7, 16364, 2015.
8. Hans M.L., and Lowman A.M. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 6, 319, 2002.
9. Cheng J., Teply B.A., Sherifi I., et al. Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28, 869, 2007.
10. Cheng X., Tsao C., Saul M., et al. Comparison of two nanoparticle formulations for localized delivery of platelet-derived growth factor (PDGF) from aligned collagen fibers. Pharm Nanotechnol 1, 105, 2013.
11. Li J., Shu Y., Hao T., et al. A chitosan–glutathione based injectable hydrogel for suppression of oxidative stress damage in cardiomyocytes. Biomaterials 34, 9071, 2013.
12. Liu D., Bimbo L.M., Mäkilä E., et al. Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. J Control Release 170, 268, 2013.
13. Connell J.P., Ruano R., and Jacot J.G. Amniotic fluid-derived stem cells demonstrate limited cardiac differentiation following small molecule-based modulation of Wnt signaling pathway. Biomed Mater 10, 034103, 2015.
14. Gao Y., Connell J.P., Wadhwa L., Ruano R., and Jacot J.G. Amniotic fluid-derived stem cells demonstrated cardiogenic potential in indirect co-culture with human cardiac cells. Ann Biomed Eng 42, 2490, 2014.
15. De Coppi P., Bartsch G., Siddiqui M.M., et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 25, 100, 2007.
16. Velasquez-Mao A.J., Tsao C.J.M., Monroe M.N., et al. Differentiation of spontaneously contracting cardiomyocytes from non-virally reprogrammed human amniotic fluid stem cells. PLoS One 12, e0177824, 2017.
17. Parodi A., Haddix S.G., Taghipour N., et al. Bromelain surface modification increases the diffusion of silica nanoparticles in the tumor extracellular matrix. ACS Nano 8, 9874, 2014.
18. Burridge P.W., Matsa E., Shukla P., et al.Chemically defined generation of human cardiomyocytes. Nat Methods 11, 855, 2014.
19. Lee S., Yun H.S., and Kim S.H. The comparative effects of mesoporous silica nanoparticles and colloidal silica on inflammation and apoptosis. Biomaterials 32, 9434, 2011.
20. Huang X., Teng X., Chen D., Tang F., and He J. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials 31, 438, 2010.
21. Zhang M., Schulte J.S., Heinick A., et al. Universal cardiac induction of human pluripotent stem cells in two and three‐dimensional formats: implications for in vitro maturation. Stem Cells 33, 1456, 2015.
22. Mashinchian O., Turner L.A., Dalby M.J., et al. Regulation of stem cell fate by nanomaterial substrates. Nanomedicine 10, 829, 2015.
23. Reimer A., Vasilevich A., Hulshof F., et al. Scalable topographies to support proliferation and Oct4 expression by human induced pluripotent stem cells. Sci Rep 6, 18948, 2016.
24. Lundy S.D., Zhu W.Z., Regnier M., and Laflamme M.A. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev 22, 1991, 2013.
25. Kamakura T., Makiyama T., Sasaki K., et al. Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. Circ J 77, 1307, 2013.
26. Cheng L., Sung M.T., Cossu-Rocca P., et al. OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. J Pathol 211, 1, 2007.
27. Burridge P.W., Holmström A., and Wu J.C. Chemically defined culture and cardiomyocyte differentiation of human pluripotent stem cells. Curr Protoc Hum Genet 87, 21.3.1, 2015.
28. Zhang J., Wilson G.F., Soerens A.G., et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 104, e30, 2009.
Information & Authors
Information
Published In
Tissue Engineering Part A
Volume 24 • Issue Number 23-24 • December 2018
Pages: 1798 - 1807
PubMed: 30129882
Copyright
Copyright 2018, Mary Ann Liebert, Inc., publishers.
History
Published online: 3 December 2018
Published in print: December 2018
Published ahead of print: 29 October 2018
Published ahead of production: 21 August 2018
Accepted: 4 June 2018
Received: 12 February 2018
Topics
Authors
Disclosure Statement
No competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.